The prevention of gastric cancer by Helicobacter pylori eradication
| Autor: | Steven F. Moss, Erick A. Argueta |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Population Gastroenterology Helicobacter Infections Resection law.invention Randomized controlled trial Stomach Neoplasms law Internal medicine Humans Medicine education Early Detection of Cancer education.field_of_study Helicobacter pylori biology business.industry digestive oral and skin physiology Cancer Neoplasms Second Primary biology.organism_classification medicine.disease United States digestive system diseases Early Gastric Cancer Search terms Etiology business |
| Zdroj: | Current Opinion in Gastroenterology. 37:625-630 |
| ISSN: | 1531-7056 0267-1379 |
| DOI: | 10.1097/mog.0000000000000777 |
| Popis: | Purpose of review Gastric cancer remains one of the most common causes of death globally. Increasing evidence suggests that many gastric cancer cases can be prevented by eradicating its most important etiological agent, Helicobacter pylori. Using the search terms 'H. pylori' and 'gastric cancer' we reviewed the scientific literature regarding the association between H. pylori and gastric cancer published from 1 January 2020 to 30 May 2021. We review the most important articles relevant to the clinical issues regarding H. pylori eradication for gastric cancer prevention. Recent findings In randomized trials, eradication of H. pylori is associated with an approximately 50% reduction in sporadic gastric cancer. A similar benefit was observed when screening first-degree relatives of gastric cancer cases, after resection of early gastric cancer to prevent metachronous neoplasia, and in population-based screen and treatment programs in areas of high H. pylori and gastric cancer prevalence. Even in relatively low gastric cancer countries such as the United States, gastric cancer may potentially be avoided by screening for H. pylori, especially among minority groups who are at greatest risk. Summary Gastric cancer is preventable, at least in part, by H. pylori eradication. Ongoing screening trials will help determine whether population-based H. pylori screening programs are feasible and cost-effective. Their results are likely to differ according to H. pylori and gastric cancer prevalence rates. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|